<DOC>
	<DOCNO>NCT01893229</DOCNO>
	<brief_summary>Background : Bipolar disorder one common mental illness affect 1 % -4 % population , one lead cause worldwide disability . Mania condition excessively elevate mood , characterize bipolar disorder , usually main cause hospitalization . Mood stabiliser antipsychotic drug long maintenance treatment acute mania without psychotic symptom . Though clinical trail demonstrate drug individually effective placebo relatively long term ( e.g 4 , 8 week ) . However , pragmatic practice , patient acute mania urgently want see effectiveness , psychiatrist great pressure great need evaluate short-term effectiveness ( e.g one week ) . If first attempt antimanic drug fails , psychiatrist need evidence medication add switch . Objectives : one main aim rank short-term ( e.g.one two week ) effectiveness acceptability common anti-mania drug , include Lithium , Valproate , Oxcarbazepine , Quetiapine , Olanzapine , Ziprasidone . Secondary aim investigate medication add non-responders switch . Methods : The study setting : expect 120 subject diagnose DSM-IV bipolar I disorder recruit Guangzhou Psychiatric Hospital , early psychiatric hospital history China establish Dr.J . G. Kerr 1898 . Design : This study randomize , control trial . Participants Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSM-IV ) diagnosis bipolar I disorder , manic mixed episode randomly assign treatment Lithium , Valproate , Oxcarbazepine , Quetiapine , Olanzapine , Ziprasidone . In follow condition , participant take another antimanic drug combination medication : 1 ) reduction YMRS score less 25 % one week treatment ; 2 ) reduction YMRS score less 50 % two week treatment ; 3 ) increase YMRS 30 % day 4 . An antipsychotic ( Quetiapine , Olanzapine , Ziprasidone ) add use lithium , Valproate Oxcarbazepine first attempt medication ; Lithium , Valproate , Oxcarbazepine add use antipsychotic first attempt medication . Those participant recognize non-response/partial response two combined medication 6 week treatment switch Modified Electroconvulsive Therapy ( MECT ) . Measures : Primary outcome measure change score Young Mania Rating Scale ( YMRS ) dropout rate . Secondary outcome measure include Clinical Global Impressions ( CGI ) Scale , Global Assessment Scale ( GAS ) , Treatment Emergent Symptom Scale ( TESS ) , Brief Psychiatric Rating Scale ( BPRS ) . Response criterion : &lt; 25 % reduction YMRS score &gt; =4 score CGI define non-response . 25-49 % reduction YMRS score baseline well &lt; =3 score Clinical General Impression ( CGI ) recognize partial response. &gt; = 50 % reduction YMRS well 1 ( much improve ) 2 score ( much improve ) CGI recognize response . Remission define YMRS score &lt; =12 CGI score equal 1 2 .</brief_summary>
	<brief_title>Comparative Efficacy Acceptability Antimanic Drugs Acute Mania</brief_title>
	<detailed_description>Background : Bipolar disorder one common mental illness affect 1 % -4 % population , one lead cause worldwide disability . Mania condition excessively elevate mood , characterize bipolar disorder , usually main cause hospitalization . Mood stabiliser antipsychotic drug long maintenance treatment acute mania without psychotic symptom . Though clinical trail demonstrate drug individually effective placebo.However , pragmatic practice , patient acute mania urgently want see effectiveness , psychiatrist great pressure great need evaluate short-term effectiveness ( e.g one week ) . If first attempt antimanic drug fails , psychiatrist need evidence medication add switch . Objectives : one main aim rank short-term ( e.g.one two week ) effectiveness acceptability common anti-mania drug , include Lithium , Valproate , Oxcarbazepine , Quetiapine , Olanzapine , Ziprasidone . Secondary aim investigate medication add non-responders switch . Methods : The study setting : expect 120 subject diagnose DSM-IV bipolar disorder recruit Guangzhou Psychiatric Hospital , early psychiatric hospital history China establish Dr.J . G. Kerr 1898 . Design : This study randomize , control trial , consist two phase . 120 participant Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSM-IV ) diagnosis bipolar I disorder , manic mixed phase randomly assign treatment Lithium , Valproate , Oxcarbazepine , Quetiapine , Olanzapine , Ziprasidone . The period start dose effective dose drug within 2 day , effective dos drug describe follow : Lithium , 750mg—2000mg/d , serum Li level : 0.6mmol—1.2mmol/L ; Valproate , 800mg -- 1200mg/d , serum Valproate level : 70-120ug/ml ; Oxcarbazepine , 600-1200mg/d ; Quetiapine , 600mg -- 800mg/d ; Olanzapine , 10mg -- 20mg/d ; Ziprasidone , 80mg—160mmg/d . In follow condition , participant take another antimanic drug combination medication : 1 ) reduction YMRS score less 25 % one week treatment ; 2 ) reduction YMRS score less 50 % two week treatment ; 3 ) increase YMRS 30 % day 4 . An antipsychotic ( Quetiapine , Olanzapine , Ziprasidone ) add use lithium , Valproate Oxcarbazepine first attempt medication ; Lithium , Valproate , Oxcarbazepine add use antipsychotic first attempt medication . Those participant recognize non-response/partial response two combined medication 6 week treatment switch Modified Electroconvulsive Therapy ( MECT ) . Measures : Primary outcome measure change score Young Mania Rating Scale ( YMRS ) dropout rate . Secondary outcome measure include Clinical Global Impressions ( CGI ) Scale , Global Assessment Scale ( GAS ) , Treatment Emergent Symptom Scale ( TESS ) , Brief Psychiatric Rating Scale ( BPRS ) . Response criterion : &lt; 25 % reduction YMRS score &gt; =4 score CGI define non-response . 25-49 % reduction YMRS score baseline well &lt; =3 score Clinical General Impression ( CGI ) recognize partial response. &gt; = 50 % reduction YMRS well 1 ( much improve ) 2 score ( much improve ) CGI recognize response . Remission define YMRS score &lt; =12 CGI score equal 1 2 .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Ziprasidone</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<mesh_term>Carbamazepine</mesh_term>
	<mesh_term>Oxcarbazepine</mesh_term>
	<criteria>diagnosis bipolar I disorder , manic mixed phase equal 18 score Young Mania Rating Scale ( YMRS ) Serious general medical illness pregnancy lactation give longacting antipsychotic drug within last two month endocrine disease ( e.g.Diabetes thyrotoxicosis ) give thyroxine therapy within last three month give hormone therapy sexually active use contraceptive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Bipolar disorder</keyword>
	<keyword>Comparative Effectiveness Research</keyword>
	<keyword>Therapeutics</keyword>
	<keyword>Patient Dropouts</keyword>
</DOC>